Clinical Trial Search

Primary: Number of Seroprotected Subjects Against Diphtheria (D) and Tetanus (T) Toxoids — 22; 35; 93; 103 Participants

Primary: Overall Objective Response Rate in Patients With Relapsed or Refractory PMLBCL — 11; 1; 1; 1 Participants

Primary: Number of Participants With Any Adverse Events (AE) or Serious Adverse Events (SAE) — 10; 7; 9; 6 Participants

Primary: Complete Clearance of Disease at Week 14 — 1; 0; 0; 0 participants — p=0.862

Primary: Number of Subjects With Best Overall Tumor Response — 1; 1; 12; 4 Participants

Primary: Maximum Plasma Concentration (Cmax) for Cannabidiol and Metabolite 7-hydroxy (7-OH) Cannabidiol — 59.03; 110.5; 256.9; 28.71 nanograms/milliliter (ng/mL)

Primary: Safety Run-In Part: Number of Subjects With Dose Limiting Toxicities (DLTs) — 0; 0; 0; 0 subjects

Primary: Effect of Drug Combination on Multiple Myeloma — 2; 9; 9; 5 participants

Primary: Efficacy of AZD7594 by Assessment of the Change From Baseline in Morning Trough Forced Expiratory Volume in 1 Second (FEV1) on Day 15 — 0.08639; 0.05948; 0.1355; 0.05948…

Primary: Number of Patients Experiencing a Dose-limiting Toxicity (Phase I) — 3; 0 Participants

Primary: Bone Mineral Density BMD of the Total Hip as Assessed by DXA. — 0.66; 0.63; 0.64; 0.65 g/cm^2 — p=0.84

Primary: Progression Free Survival (PFS) — 5.5 Months

Primary: Safety and Efficacy of High Dose Carfilzomib — 3; 13 Participants

Primary: Percentage Change From Baseline in Low-Density Lipoprotein Cholesterol (LDL-C) — 7.6; -14.9; -40.5; -50.5 Percentage change

Primary: Confirmed Objective Response Rate (ORR) as Assessed by Investigator — 45.5; 57.3 percentage of participants